“…In a multicentre, phase 2, open-label, randomised, controlled study, safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of three different once-weekly doses of MOD-4023were compared to once-daily recombinant human GH (r-hGH) in prepubertal children with GHD for 12 months of treatment, revealing the better efficacy of 0.66 mg/kg/week dose along with a good tolerability and safety [61]. In a randomised, open-label, active-controlled study of 3 doses of once-weekly TransCon GH, a long-acting sustained-release r-hGH prodrug, compared to once-daily Genotropin; both drugs were comparable in the context of safety and efficacy [62]. Finally, in a phase 2 and 3, open-label, multicentre, randomised studies with a long-acting PEGylated r-hGH (0.2 mg/kg/week), when compared to once-daily rhGH (0.25 mg/kg/week) for 25 weeks in children with GHD, the former was shown to be effective and safe for GHD treatment [63] (Table 3).…”